The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma

Authors

  • Nahid Punjani Division of Urology, Department of Surgery, Western University, London, Ontario
  • Roderick Clark Division of Urology, Department of Surgery, Western University, London, Ontario
  • Jonathan Izawa Division of Urology, Department of Surgery, Western University, London, Ontario Division of Surgical Oncology, Department of Oncology, Western University, London, Ontario
  • Joseph Chin Division of Urology, Department of Surgery, Western University, London, Ontario Division of Surgical Oncology, Department of Oncology, Western University, London, Ontario
  • Stephen E. Pautler Division of Urology, Department of Surgery, Western University, London, Ontario Division of Surgical Oncology, Department of Oncology, Western University, London, Ontario
  • Nicholas Power Division of Urology, Department of Surgery, Western University, London, Ontario Division of Surgical Oncology, Department of Oncology, Western University, London, Ontario

DOI:

https://doi.org/10.5489/cuaj.4650

Abstract

Introduction: Adrenal cortical carcinoma (ACC) is a rare and aggressive endocrine tumour. Most present with advanced disease and have poor prognosis. Optimal treatment includes complete surgical resection. There is limited evidence for the efficacy of chemotherapy and radiation at different stages in this disease. There remain many inconsistencies with respect to diagnosis and workup. There is a lack of uniform guideline recommendations and consensus data.

Methods: We performed a retrospective chart review of all patients at London Health Sciences Centre between 1990 and 2015 using ICD coding. All paper and electronic charts were reviewed and data was collected. Statistical analysis and survival curves were performed.

Results: A total of 29 patients were included in our study. Median age was 55 years (interquartile range [IQR] 45–63); 14 (48%) were male and 15 (52%) were female. Approximately half (14 or 48%) of our patients presented symptomatically. Almost half (41%) of tumours were metabolically active, producing hormones. Most (88%) underwent surgical intervention. Surgical margin status was available in about half of patients and lymphadenectomy was performed in a third (n=8) of open adrenalectomy patients. A third received mitotane treatment (8 [73%] adjuvant and 3 [27%] palliative) and a third of patients received radiation. Two- and five-year median overall survival was 53% and 27%, respectively.

Conclusions: ACC is a rare and aggressive tumour. This is the largest Canadian series reported to the best of our knowledge. Limited data for guidelines exists and treatment and workup patterns are inconsistent. Collaborative randomized and prospective studies on a global basis are needed.

Downloads

Download data is not yet available.

Downloads

Published

2017-12-16

How to Cite

Punjani, N., Clark, R., Izawa, J., Chin, J., Pautler, S. E., & Power, N. (2017). The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma. Canadian Urological Association Journal, 12(4), 98–103. https://doi.org/10.5489/cuaj.4650

Issue

Vol. 12 No. 4 (2018): CUAJ April

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.